The Role Of B Cell Specific MHC II Antigen Presentation In Breast Cancer Progression And Immune Checkpoint Blockade Therapy 2310330

Abstract Introduction Breast cancer remains the leading cause of cancer-related mortality in women. Immunotherapies have revolutionized treatment; however, their efficacy relies heavily on immune cell-mediated antigen (ag) presentation within the tumor microenvironment (TME). The often overlooked role of B cell ag presentation may be important in anti-tumor immunity. B cells are potent ag presenting cells and therole of B cell ag presentation in progression of mouse models of autoimmune diseases has been demonstrated. B cells may have a potent role in breaking immune tolerance towards self-peptides. We hypothesize that B cell specific MHC II ag presentation plays a non-redundant role in promoting anti-tumor immunity. Methods To investigate the role of B cell MHC II ag presentation in tumor progression, we generated B cell-specific MHC II knockout mice and utilized the E0771, a murine triple-negative breast cancer (TNBC), and E0771-LN26 cell line with a propensity for lymph node and metastases. Tumor growth was assessed in B cell MHC II-deficient and wild-type littermates. We also assessed tumor growth in anti-PD-1 treated condition. To understand the relevance of this study in human TNBCs, we generated co-relation of MHC II expression in breast cancer on patient outcome, we analyzed publicly available TNBC data. Results Our data demonstrate that E0771 and E0771-LN2 tumors exhibit accelerated growth in B cell-specific MHC II knockout mice compared to MHC II fl/fl controls, highlighting a critical role for B cell-mediated MHC II ag presentation in controlling tumor progression. Moreover, T cells from mice lacking B cell specific MHC II expression had were more exhausted. Intrestingly, mice lacking B cell MHC II expression were more responsive to anti-PD-1 treatment. We also found a co-relation of high MHC II expression with better patient outcome. Conclusion These findings suggest that B cell-mediated antigen presentation plays a context dependent role in modulating anti-tumor immune responses in breast cancer. Funding Source This research project is supported by funding from NCI Topic Categories Classical and Non-Classical Antigen Presenting Cells (APC)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2026-07-28
DOI
https://doi.org/10.1093/jimmun/vkag141.1746
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role Of B Cell Specific MHC II Antigen Presentation In Breast Cancer Progression And Immune Checkpoint Blockade Therapy 2310330

Chunru Lin, Chaitali Bhadiadra, Liuqing Yang, Gao Jian
The Journal of Immunology
Immunotherapy and Immune Responses
article

The Role Of B Cell Specific MHC II Antigen Presentation In Breast Cancer Progression And Immune Checkpoint Blockade Therapy 2310330

Chunru Lin, Chaitali Bhadiadra, Liuqing Yang, Gao Jian
article en

Abstract

Abstract Introduction Breast cancer remains the leading cause of cancer-related mortality in women. Immunotherapies have revolutionized treatment; however, their efficacy relies heavily on immune cell-mediated antigen (ag) presentation within the tumor microenvironment (TME). The often overlooked role of B cell ag presentation may be important in anti-tumor immunity. B cells are potent ag presenting cells and therole of B cell ag presentation in progression of mouse models of autoimmune diseases has been demonstrated. B cells may have a potent role in breaking immune tolerance towards self-peptides. We hypothesize that B cell specific MHC II ag presentation plays a non-redundant role in promoting anti-tumor immunity. Methods To investigate the role of B cell MHC II ag presentation in tumor progression, we generated B cell-specific MHC II knockout mice and utilized the E0771, a murine triple-negative breast cancer (TNBC), and E0771-LN26 cell line with a propensity for lymph node and metastases. Tumor growth was assessed in B cell MHC II-deficient and wild-type littermates. We also assessed tumor growth in anti-PD-1 treated condition. To understand the relevance of this study in human TNBCs, we generated co-relation of MHC II expression in breast cancer on patient outcome, we analyzed publicly available TNBC data. Results Our data demonstrate that E0771 and E0771-LN2 tumors exhibit accelerated growth in B cell-specific MHC II knockout mice compared to MHC II fl/fl controls, highlighting a critical role for B cell-mediated MHC II ag presentation in controlling tumor progression. Moreover, T cells from mice lacking B cell specific MHC II expression had were more exhausted. Intrestingly, mice lacking B cell MHC II expression were more responsive to anti-PD-1 treatment. We also found a co-relation of high MHC II expression with better patient outcome. Conclusion These findings suggest that B cell-mediated antigen presentation plays a context dependent role in modulating anti-tumor immune responses in breast cancer. Funding Source This research project is supported by funding from NCI Topic Categories Classical and Non-Classical Antigen Presenting Cells (APC)

The Journal of ImmunologyVol. 215(Supplement_1)
The University of Texas MD Anderson Cancer Center (US), Scripps MD Anderson Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 14%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.